Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: A review and update

Advances in Anatomic Pathology

Volumn 13, Issue 1, 2006, Pages 16-25

  Ordóñez, Nelson G ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

D2 40; Immunohistochemistry; Peritoneal mesothelioma; Podoplanin; Serous carcinoma

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; ESTROGEN RECEPTOR; KERATIN; KERATIN 5; KERATIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY BER EP4; MONOCLONAL ANTIBODY BG 8; MONOCLONAL ANTIBODY D2 40; MONOCLONAL ANTIBODY MOC 31; PODOPLANIN; PROGESTERONE RECEPTOR; THROMBOMODULIN; UNCLASSIFIED DRUG; CALBINDIN; HUMAN EPITHELIAL ANTIGEN 125; HUMAN EPITHELIAL ANTIGEN-125; TUMOR MARKER;

CYSTADENOCARCINOMA; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY; PERITONEUM; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; CHEMISTRY; FEMALE; MESOTHELIOMA; NEOPLASM; OVARY TUMOR; PERITONEUM TUMOR; SENSITIVITY AND SPECIFICITY;

CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTORS, ESTROGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33644941762     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/01.pap.0000201832.15591.1d     Document Type: Review

References (83)

1. Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol. 2002;33:953-967.
2. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36:372-380.
3. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
4. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int. 2005;55:83-86.
5. Sienko A, Zander DS, Killen D, et al. D2-40 is a novel new marker of malignant mesothelioma (MM): Tissue microarray study of 45 MM versus 409 lung carcinomas and primary non-mesothelial neoplasms of the pleura and chest wall. Mod Pathol. 2005;18:318A.
6. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer. 1999;80:569-578.
7. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913-921.
8. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006;19:34-48.
9. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
10. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract. 1996;192:137-147.
11. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol. 1998;11:929-933.
12. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55:662-668.
13. Barberis MCP, Faleri M, Veronese S, et al. Calretinin: a selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol. 1997;41:1757-1761.
14. Brockstedt U, Gulyas M, Dobra K, et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol. 2000;114:203-209.
15. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25:43-50.
16. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529-536.
17. Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13:107-112.
18. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
19. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology. 1998;32:209-216.
20. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
21. Simsir A, Fetsch P, Abati A. Calretinin immunostaining in benign and malignant pleural effusions. Diagn Cytopathol. 2001;24:149-152.
22. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer. 2001;92:2727-2732.
23. Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer. 2000;90:312-319.
24. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002;40:237-244.
25. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203-1214.
26. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005;36:195-201.
27. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol. 1992;141:827-833.
28. Brown RW, Clark GM, Tandon AK, et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993;24:347-354.
29. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol. 1997;21:1399-1408.
30. Ordóñez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology. 1997;31:25-30.
31. Attanoos RL, Appleton MAC, Goddard H, et al. Thrombomodulin expression in malignant peritoneal mesothelioma and serous papillary adenocarcinoma of the ovary. J Pathol. 1995;176:S49A.
32. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology. 1997;31:140-143.
33. Ordóñez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998;22:1215-1221.
34. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
35. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
36. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol. 1995;146:344-356.
37. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med. 2001;125:1316-1320.
38. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol. 1997;181:67-74.
39. Miettinen M, Limon J, Niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-617.
40. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: as assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341-347.
41. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115.
42. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol. 2001;116:246-252.
43. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-545.
44. Hashi A, Yuminamochi T, Murate S-I, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003;22:374-377.
45. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004;17:476-481.
46. Ordóñez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005;36:1163-1167.
47. Carano KS, Soslow RA. Immunophenotypic analysis of ovarian and testicular Müllerian papillary serous tumors. Mod Pathol. 1997;10:414-420.
48. Halperin R, Zehavi S, Hadas E, et al. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol. 2001;20:341-345.
49. Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-a expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol. 2001;25:667-672.
50. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol. 2001;20:155-159.
51. Lindgren PR, Cajander S, Bäckström T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol. 2004;221:97-104.
52. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004;17:790-797.
53. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol. 1998;29:166-169.
54. Edwards C, Oates J. OV632 and MOC-31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed paraffin wax embedded material. J Clin Pathol. 1995;48:626-630.
55. Winter MJ, Nagtegaal ID, van Krieken JHJM, et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163:2139-2148.
56. Cherchi PL, Marras V, Capobianco G, et al. Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results. Eur J Gynaecol Oncol. 2001;22:433-435.
57. Rothacker D, Möbius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. Int J Gynecol Pathol. 1995;14:310-318.
58. Thor A, Gorstein F, Ohuchi N, et al. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst. 1986;76:995-1006.
59. Bollinger DJ, Wick MR, Dehner LP, et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: a histochemical and immunohistochemical comparison. Am J Surg Pathol. 1989;13:659-670.
60. Khoury N, Raju U, Crissman JD, et al. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol. 1990;21:811-819.
61. Wick MR, Mills SE, Dehner LP, et al. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol. 1989;8:179-188.
62. Sheibani K, Battifora H, Burke JS, et al. Leu-M1 antigen in human neoplasms: an immunohistologic study of 400 cases. Am J Surg Pathol. 1986;10:227-236.
63. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol. 1986;123:212-219.
64. Wick MR, Mills SE, Swanson PE. Expression of 'myelomonocytic' antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol. 1990;94:18-26.
65. González-Lois C, Ballentín C, Sotelo MT, et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology. 2001;38:528-534.
66. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409-1419.
67. Gaffey MJ, Mills SE, Swanson PE, et al. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol. 1992;16:593-599.
68. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491-497.
69. Ordóñez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol. 1987;26:1-10.
70. Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489-5492.
71. Oshio G, Yamaki K, Imamura T, et al. Distribution of the carbohydrate antigens, DU-PAN-2 and CA19-9, in tumors of the lung. Tumori. 1995;81:67-73.
72. Chenard-Neu MP, Bellocq JP, Maier A, et al. Mésothéliomes malins de la plévre. Analyse de leurs aspects immunohistochemiques. Ann Pathol. 1990;10:20-27.
73. Wick MR, Swanson PE, Manivel JC. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol. 1987;18:946-954.
74. Truong LD, Maccato ML, Awalt H, et al. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol. 1990;21:99-110.
75. Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women: a clinicopathologic and immunohistochemical study. Cancer. 1995;76:429-436.
76. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
77. Gitsch G, Tabery U, Feigl W, et al. The differential diagnosis of primary peritoneal papillary tumors. Arch Gynecol Obstet. 1992;251:139-144.
78. Gogate N, Deshmukh S. Immunohistochemical localization of carcinoembryonic antigen (CEA) in malignant epithelial ovarian tumours using monoclonal antibodies. Indian J Pathol Microbiol. 1995;38:199-201.
79. Jothy S, Brazinsky SA, Chin-A-Loy M, et al. Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity. Lab Invest. 1986;54:108-117.
80. Neunteuffel W, Breitenecker G. Tissue expression of CA125 in benign and malignant lesions of the ovary and fallopian tube: a comparison with CA19-9 and CEA. Gynecol Oncol. 1989;32:297-302.
81. Sheahan K, O'Brien MJ, Burke B, et al. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol. 1990;94:157-164.
82. Silcocks PB, Herbert A, Wright DH. Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary. J Pathol. 1986;149:133-141.
83. White PF, Merino MJ, Barwick KW. Serous surface papillary carcinoma of the ovary. A clinical, pathologic, ultrastructural and immunohistochemical study of 11 cases. Pathol Annu. 1985;20:403-418.